Rho J P, Castle S, Smith K, Bawdon R E, Norman D C
Pharmacy Service, West Los Angeles Medical Center, California 90073.
J Antimicrob Chemother. 1992 Jun;29(6):701-9. doi: 10.1093/jac/29.6.701.
The pharmacokinetics of cefoperazone 2 g combined with sulbactam 1 g after a single dose administered intravenously were evaluated in 24 subjects with normal and impaired renal function. Subjects were categorized into four groups based on endogenous creatinine clearance Clcr. Patients in groups 1, 2 and 3 had ClcrS of greater than 60, 31 to 60, and 10 to 30 mL/min/1.73 m2, respectively. Patients in group 4 required maintenance haemodialysis and were assumed to have Clcr less than 10 mL/min/1.73 m2. Pharmacokinetic parameters were determined by noncompartmental methods. No significant differences (P greater than 0.05) in mean peak serum cefoperazone-sulbactam concentrations for group 1 (208.4/29.0 mg/L), group 2 (199.0/34.1 mg/L), group 3 (163.2/35.0 mg/L), and group 4 (234.0/66.0 mg/L) were noted. Correlations between both total serum (r = 0.58) and renal (r = 0.35) clearance and creatinine clearances were negative for cefoperazone, although both were shown to decline with diminished renal function. Correlations between serum (r = 0.85) and renal (r = 0.72) clearances and creatinine clearance for sulbactam were, on the other hand, both positive and declined in a linear fashion. No significant differences in steady state volumes of distribution were noted for either cefoperazone (P = 0.53) or sulbactam (P = 0.85) amongst the four groups. After 24 h, urinary recovery was also comparable for both cefoperazone (P = 0.64) and sulbactam (P = 0.85) amongst the four groups. The concentrations of cefoperazone and sulbactam remained at or above the MICs (16/8 mg/L) for common bacterial pathogens for 2.5, 3, 7 and 14 h in groups 1, 2, 3 and 4, respectively.
在24例肾功能正常和受损的受试者中评估了静脉注射单剂量2克头孢哌酮联合1克舒巴坦后的药代动力学。根据内生肌酐清除率(Clcr)将受试者分为四组。第1、2和3组患者的ClcrS分别大于60、31至60和10至30 mL/min/1.73 m²。第4组患者需要维持性血液透析,假定其Clcr小于10 mL/min/1.73 m²。采用非房室模型方法确定药代动力学参数。第1组(208.4/29.0 mg/L)、第2组(199.0/34.1 mg/L)、第3组(163.2/35.0 mg/L)和第4组(234.0/66.0 mg/L)的头孢哌酮-舒巴坦血清平均峰浓度无显著差异(P大于0.05)。头孢哌酮的总血清清除率(r = 0.58)和肾脏清除率(r = 0.35)与肌酐清除率之间的相关性均为负,尽管两者均显示随着肾功能减退而下降。另一方面,舒巴坦的血清清除率(r = 0.85)和肾脏清除率(r = 0.72)与肌酐清除率之间的相关性均为正,且呈线性下降。四组中头孢哌酮(P = 0.53)或舒巴坦(P = 0.85)的稳态分布容积均无显著差异。24小时后,四组中头孢哌酮(P = 0.64)和舒巴坦(P = 0.85)的尿回收率也相当。第1、2、3和4组中头孢哌酮和舒巴坦的浓度分别在2.5、3、7和14小时内保持在常见细菌病原体的MICs(16/8 mg/L)或以上。